Want to brand your business without breaking the bank? The best free logo maker will be an essential tool in your marketing kit - and after testing these completely free logo designers ...

We've been getting creative with the best logo makers for branding your business online. It's difficult to understate the importance of good logo design - it's the quickest way for customers and ...

Of course, some criticize these modern logos as being copy-and-paste, minimalist and unoriginal. Those yearn to return to the unique logos of the 1990s and early 2000s, where the NFL used elements ...

While accepting the award, Owen shouted a popular Malaysian phrase often heard during Chinese New Year: "Heng Ong Huat!" The 37-year-old then thanked his Malaysian fans for voting for him in his ...

Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer ...

Every day, no matter where she is, Sulinna Ong puts away her phone, turns off all notifications and lies down on the floor for three hours to listen to new songs. Ong oversees 130 Spotify ...

Sanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a second-line therapy in cervical cancer, setting up regulatory filings ...

Walmart steel cage match (although we would totally watch). Instead, Walmart gave its logo a makeover fit for modern times—at least that was the idea. But people, well, they have feelings.

Walmart announced on Monday that it had unveiled a new logo, part of "a comprehensive brand refresh." The U.S.-based retailer boasted in a news release that the new look — its first change ...

Regeneron Pharmaceuticals, Inc. announced positive results from the phase 3 C-POST trial, which demonstrated that adjuvant treatment with PD-1 inhibitor Libtayo (cemiplimab) led to a statistically ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...